251 related articles for article (PubMed ID: 28285694)
1. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
2. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Weickhardt AJ; Scheier B; Burke JM; Gan G; Lu X; Bunn PA; Aisner DL; Gaspar LE; Kavanagh BD; Doebele RC; Camidge DR
J Thorac Oncol; 2012 Dec; 7(12):1807-1814. PubMed ID: 23154552
[TBL] [Abstract][Full Text] [Related]
3. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
5. Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor.
Ng TL; Morgan RL; Patil T; Barón AE; Smith DE; Ross Camidge D
Lung Cancer; 2018 Dec; 126():112-118. PubMed ID: 30527174
[TBL] [Abstract][Full Text] [Related]
6. Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.
Borghetti P; Bonù ML; Giubbolini R; Levra NG; Mazzola R; Perna M; Visani L; Meacci F; Taraborrelli M; Triggiani L; Franceschini D; Greco C; Bruni A; Magrini SM; Scotti V
Radiol Med; 2019 Jul; 124(7):662-670. PubMed ID: 30771218
[TBL] [Abstract][Full Text] [Related]
7. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
[TBL] [Abstract][Full Text] [Related]
8. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.
Langston J; Patil T; Ross Camidge D; Bunn PA; Schenk EL; Pacheco JM; Jurica J; Waxweiler TV; Kavanagh BD; Rusthoven CG
Lung Cancer; 2023 Apr; 178():103-107. PubMed ID: 36809719
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
10. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy beyond targeted therapy in lung adenocarcinoma.
Ho JC; Tam TC; Lam SK
Semin Respir Crit Care Med; 2013 Dec; 34(6):837-44. PubMed ID: 24258573
[TBL] [Abstract][Full Text] [Related]
12. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
13. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
[TBL] [Abstract][Full Text] [Related]
14. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.
Zhao N; Zheng SY; Yang JJ; Zhang XC; Xie Z; Xie B; Su J; Chen ZH; Chen SL; Zhang N; Lou NN; Dong S; Wu YL
Clin Lung Cancer; 2015 Mar; 16(2):e5-9. PubMed ID: 25496960
[No Abstract] [Full Text] [Related]
15. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
16. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
17. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic options for oligoprogressive non-small cell lung cancer].
Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
[TBL] [Abstract][Full Text] [Related]
19. ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
Chan OSH; Lam KC; Li JYC; Choi FPT; Wong CYH; Chang ATY; Mo FKF; Wang K; Yeung RMW; Mok TSK
Lung Cancer; 2020 Apr; 142():41-46. PubMed ID: 32088604
[TBL] [Abstract][Full Text] [Related]
20. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
